A Study On The Association Of RAGE Gene Polymorphism With EH/LVH And Serum Level Of EsRAGE

Background and ObjectiveEssential hypertension is a multigenic hereditary disease which results from interaction of genetic factors and environmental factors. Therefore, defining susceptibility genes is very important for its early diagnosis and treatment. In recent years, more and more people have been interested in the study of RAGE gene polymorphism. Previous studies had shown that variation of the functional amino acid on RAGE polymorphic sites is related to cardiovascular diseases.To study the association of RAGE gene Gly82Ser polymorphism and serum esRAGE level with EH and LVH occurrence, and investigate the relationship between Gly82Ser polymorphism of RAGE gene and serum esRAGE level in essential hypertension patients, in order to implore the role of RAGE and its polymorphism in the pathogenesis of EH and EH with LVH.MethodsScreen out 94 EH patients from our hypertension outpatient clinics as case group and 50 as control group. All of the people were required to undergo medical examination including weight, electrocardiogram, chest X-ray, blood glucose, triglyceride and cholesterol. In case group, echocardiography was performed to calculate the left ventricular mass index.38 cases of EH-LVH in case group were screened out as EH-LVH group and the remaining 56 cases as EH-NLVH group according to the diagnostic criteria of left ventricular hypertrophy (LVMI values, male>125g/m2, female>110g/m2). PCR-restriction fragment length polymorphism (PCR-RFLP) method was used to analyze the correlation of polymorphisms of RAGE gene between case group and control group. ELISA was used to detect the serum level of esRAGEResultsThere was no significant difference of the alleles and genotype frequencies of RAGE gene Gly82Ser polymerphism between case group and control group (P>0.05). The frequencies of RAGE gene Gly82Ser GS/SS genotype and S allele in EH with LVH were significantly higher than control group (P<0.05).Comparing with control group, levels of the serum esRAGE in EH-LVH group and EH-NLVH group were both lower in EH patients (0.24±0.08ng/ml vs 0.30±0.08ng/ml, P<0.05; 0.26±0.09ng/ml vs 0.30±0.08ng/ml, P<0.05); there was no significant difference between EH-LVH group and EH-NLVH group.In EH-LVH group, EH-NLVH group and control group, the level of the serum esRAGE in Gly82Ser SS genotype of RAGE gene were all higher than those in Gly82Ser SS/GS genotype (0.27±0.09ng/l vs 0.21±0.05ng/l, P<0.05; 0.29±0.09ng/l vs 0.22±0.07ng/l, P< 0.05; 0.32±0.08ng/l vs 0.26±0.07ng/l, P<0.05).ConclusionRAGE gene Gly82Ser Polymorphism did not demonstrate any association with the prevalence of essential hypertension. The frequencies of RAGE gene Gly82Ser GS/SS genotype and S allele were significantly higher in patients with EH-LVH which implied GS/SS genotype and S allele may be susceptibility gene in the occurrence of EH-LVH. In contrast, the level of esRAGE was very low in EH patients especially in EH-LVH patients which means that esRAGE may be a protective factor in the occurrence of EH and EH-LVH. A significant relationship has been found between the polymorphism of the RAGE gene and the serum levels of esRAGE in EH and EH-LVH patients, which implied that genemutation of RAGE has a cross-reaction with the secrete mechanism of esRAGE.